HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chattem To Revive Rolaids Line Bought From J&J

This article was originally published in The Tan Sheet

Executive Summary

Chattem snaps up Rolaids from Johnson & Johnson subsidiary McNeil, which never restocked the iconic heartburn relief brand after recalling and suspending production in 2010. Sanofi touts Rolaids as “an enduring brand with a deep heritage.”

You may also be interested in...



Nexium OTC Switch Would Face Crowded Field, Potential Questions

Pfizer will pay AstraZeneca $250 million upfront for global rights to market a potential OTC 20-mg Nexium. Pharma marketing expert Joe McGovern expects Nexium “to start OTC with a big bang,” but Center for Consumer Self Care Executive Director Bill Soller points to potential safety questions about a switch.

Ilex Revitalizes Di-gel And St. Joseph Aspirin Lines Before Relaunching

Ilex Consumer Products Group plans to make its mark in the consumer health care products arena by relaunching and “revitalizing iconic American brands,” including the recently acquired di-gel digestive relief brand and St. Joseph Aspirin.

FDA Enforces Consent Decree Over J&J/McNeil's OTC Manufacturing

FDA will wield tight oversight of Johnson & Johnson subsidiary McNeil Consumer Healthcare's OTC manufacturing operations under a consent decree filed after the firm's quality-control changes failed to satisfy the agency.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS124508

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel